Short communication · 11 Oct 2022
Research articlePublished 2015
Duration of Chemotherapies in Phase III Studies on Metastatic Colorectal Cancer Treated With a Continuous Approach: A Seven-Year Survey
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In last years, many phase III studies have addressed the role of chemotherapy or chemo/biotherapy in metastatic colorectal cancer (mCRC); most of these studies planned their treatment to be continued until disease progression or intolerable toxicity with the aim to obtain a long-term control of the cancer. However, the real duration of this approach might be significantly lower than planned. We made a survey to describe the real duration of chemotherapy in published phase III trials from January 2008 to December 2014. Twenty relevant publications were selected for a total of 48 treatment arms and of 24.475 patients. Median duration of chemotherapy in first-line studies ranged from 4,8 to 7,8 months; in second line from 2,4 to 5,2 months. Most common reasons of discontinuation were: progressive disease (PD), adverse events (AE) and patient request (PR). From 11.0% to 45.0% of patients discontinue treatment for toxicity or their request independently from the efficacy. PR was the third cause ranging from 4,6% to 26,0% of patients; in some studies, it overcame the AE-related withdrawals. Causes of PR for therapy discontinuation should be explored and analyzed to reduce the proportion of withdrawals in phase III studies.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 2022
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with Regorafenib and PD-1 Inhibitors in the Treatment of Liver Metastases of Colorectal Cancer after Failure of Second-Line Chemotherapy: A Single-Arm Prospective, Open-Label Phase II Clinical Trial
Research article · 2018
Multiline Chemotherapy for Elderly Patients with Metastatic Colorectal Cancer: A Single Center Experience.
Editorial · 2012
Port Free Chemotherapy for Recurrent or Metastatic Colorectal Cancer. Is Port Really Necessary?
Conference abstract · 10 Sep 2012
Safety and efficacy of non-pegylated liposomal doxorubicin (NPLD) at two different dose levels as compared to conventional doxorubicin in patients (pts) with metastatic breast cancer (MBC): A phase II/III open label mult
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Alessandro Ottaiano”
- BylineArticles whose byline prints “Maurizio Capuozzo”
- BylineArticles whose byline prints “Guglielmo Nasti”
- BylineArticles whose byline prints “Anna Nappi”
- BylineArticles whose byline prints “Chiara De Divitiis”
- BylineArticles whose byline prints “Monica Capozzi”
- BylineArticles whose byline prints “Salvatore Tafuto”
- BylineArticles whose byline prints “Piera Maiolino”

